These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 9010717)

  • 1. The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response.
    Boussiotis VA; Freeman GJ; Gribben JG; Nadler LM
    Immunol Rev; 1996 Oct; 153():5-26. PubMed ID: 9010717
    [No Abstract]   [Full Text] [Related]  

  • 2. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?
    van Gool SW; Barcy S; Devos S; Vandenberghe P; Ceuppens JL; Thielemans K; de Boer M
    Res Immunol; 1995; 146(3):183-96. PubMed ID: 8525052
    [No Abstract]   [Full Text] [Related]  

  • 3. The complexities of T-cell co-stimulation: CD28 and beyond.
    Sperling AI; Bluestone JA
    Immunol Rev; 1996 Oct; 153():155-82. PubMed ID: 9010723
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of CTLA-4 in the regulation and initiation of T-cell responses.
    Chambers CA; Krummel MF; Boitel B; Hurwitz A; Sullivan TJ; Fournier S; Cassell D; Brunner M; Allison JP
    Immunol Rev; 1996 Oct; 153():27-46. PubMed ID: 9010718
    [No Abstract]   [Full Text] [Related]  

  • 5. CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.
    Linsley PS; Ledbetter J; Peach R; Bajorath J
    Res Immunol; 1995; 146(3):130-40. PubMed ID: 8525042
    [No Abstract]   [Full Text] [Related]  

  • 6. Transplantation and the CD28/CTLA4/B7 pathway.
    Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
    Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
    [No Abstract]   [Full Text] [Related]  

  • 7. CTLA-4 and T cell activation.
    Oosterwegel MA; Greenwald RJ; Mandelbrot DA; Lorsbach RB; Sharpe AH
    Curr Opin Immunol; 1999 Jun; 11(3):294-300. PubMed ID: 10375557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD28 function: a balance of costimulatory and regulatory signals.
    Bour-Jordan H; Blueston JA
    J Clin Immunol; 2002 Jan; 22(1):1-7. PubMed ID: 11958588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of T cell anergy in the absence of CTLA-4/B7 interaction.
    Frauwirth KA; Alegre ML; Thompson CB
    J Immunol; 2000 Mar; 164(6):2987-93. PubMed ID: 10706686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
    Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
    Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
    Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
    J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
    Lane P
    Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.
    Bai XF; Liu J; May KF; Guo Y; Zheng P; Liu Y
    Blood; 2002 Apr; 99(8):2880-9. PubMed ID: 11929778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
    Liu Z; Geboes K; Hellings P; Maerten P; Heremans H; Vandenberghe P; Boon L; van Kooten P; Rutgeerts P; Ceuppens JL
    J Immunol; 2001 Aug; 167(3):1830-8. PubMed ID: 11466409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance.
    Eagar TN; Karandikar NJ; Bluestone JA; Miller SD
    Eur J Immunol; 2002 Apr; 32(4):972-81. PubMed ID: 11920563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
    Freeman GJ; Gribben JG; Boussiotis VA; Ng JW; Restivo VA; Lombard LA; Gray GS; Nadler LM
    Science; 1993 Nov; 262(5135):909-11. PubMed ID: 7694363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance.
    Boussiotis VA; Gribben JG; Freeman GJ; Nadler LM
    Curr Opin Immunol; 1994 Oct; 6(5):797-807. PubMed ID: 7530013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the B7-CD28/CTLA-4 pathway in autoimmune disease.
    Chang TT; Kuchroo VK; Sharpe AH
    Curr Dir Autoimmun; 2002; 5():113-30. PubMed ID: 11826754
    [No Abstract]   [Full Text] [Related]  

  • 19. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses.
    Zhang YQ; Joost van Neerven RJ; Van Gool SW; Coorevits L; de Boer M; Ceuppens JL
    Int Immunol; 1997 Aug; 9(8):1095-102. PubMed ID: 9263006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.
    Perez VL; Van Parijs L; Biuckians A; Zheng XX; Strom TB; Abbas AK
    Immunity; 1997 Apr; 6(4):411-7. PubMed ID: 9133420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.